Potentiation of nuclear ERK signaling in the brain via KPNA2/7 binding has potential benefits in terms of both enhancing cognition in normal aging and providing protection and cognitive enhancement in the context of major disorders such as AD, PD, and HD. This evidence concerns the gene MAPK1 and Parkinson disease.